Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: Results from a population-based study of prostate cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  FitzGerald, Liesel M ^a   Agalliu, Ilir ^a,b   Johnson, Karynn ^c   Miller, Melinda A ^d   Kwon, Erika M ^e   Hurtado Coll, Antonio ^c   Fazli, Ladan ^c   Rajput, Ashish B ^c   Gleave, Martin E ^c   Cox, Michael E ^c   Ostrander, Elaine A ^e   Stanford, Janet L ^a,f   Huntsman, David G ^c,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; SERINE PROTEINASE; THYMINE; TRANSCRIPTION FACTOR ERG; TRANSMEMBRANE SERINE PROTEINASE 2; ONCOPROTEIN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FUSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PROSTATE CANCER; PROSTATECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TRANSURETHRAL RESECTION; GENETICS; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 50549095607     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-230     Document Type: Article

References (37)

1. Petrovics G Liu A Shaheduzzaman S Furusato B Sun C Chen Y Nau M Ravindranath L Chen Y Dobi A Srikantan V Sesterhenn IA McLeod DG Vahey M Moul JW Srivastava S: Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005, 24(23):3847-3852. 10.1038/sj.onc.1208518 15750627
2. Tomlins SA Rhodes DR Perner S Dhanasekaran SM Mehra R Sun XW Varambally S Cao X Tchinda J Kuefer R Lee C Montie JE Shah RB Pienta KJ Rubin MA Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648. 10.1126/ science.1117679 16254181
3. Cerveira N Ribeiro FR Peixoto A Costa V Henrique R Jeronimo C Teixeira MR: TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006, 8(10):826-832. 1715930 17032499 10.1593/ neo.06427
4. Nam RK Sugar L Yang W Srivastava S Klotz LH Yang LY Stanimirovic A Encioiu E Neill M Loblaw DA Trachtenberg J Narod SA Seth A: Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007, 97(12):1690-1695. 10.1038/sj.bjc.6604054 17971772
5. Perner S Demichelis F Beroukhim R Schmidt FH Mosquera JM Setlur S Tchinda J Tomlins SA Hofer MD Pienta KG Kuefer R Vessella R Sun XW Meyerson M Lee C Sellers WR Chinnaiyan AM Rubin MA: TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006, 66(17):8337-8341. 10.1158/ 0008-5472.CAN-06-1482 16951139
6. Soller MJ Isaksson M Elfving P Soller W Lundgren R Panagopoulos I: Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006, 45(7):717-719. 10.1002/ gcc.20329 16575875
7. Wang J Cai Y Ren C Ittmann M: Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006, 66(17):8347-8351. 10.1158/0008-5472.CAN-06-1966 16951141
8. Mehra R Han B Tomlins SA Wang L Menon A Wasco MJ Shen R Montie JE Chinnaiyan AM Shah RB: Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 2007, 67(17):7991-7995. 10.1158/0008-5472.CAN-07-2043 17804708
9. Clark J Merson S Jhavar S Flohr P Edwards S Foster CS Eeles R Martin FL Phillips DH Crundwell M Christmas T Thompson A Fisher C Kovacs G Cooper CS: Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26(18):2667-2673. 10.1038/sj.onc.1210070 17043636
10. Furusato B Gao CL Ravindranath L Chen Y Cullen J McLeod DG Dobi A Srivastava S Petrovics G Sesterhenn IA: Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008, 21(2):67-75. 18065961
11. Tu JJ Rohan S Kao J Kitabayashi N Mathew S Chen YT: Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: Frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007, 20(9):921-928. 10.1038/modpathol.3800903 17632455
12. Hermans KG van Marion R van Dekken H Jenster G van Weerden WM Trapman J: TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006, 66(22):10658-10663. 10.1158/0008-5472.CAN-06-1871 17108102
13. Iljin K Wolf M Edgren H Gupta S Kilpinen S Skotheim RI Peltola M Smit F Verhaegh G Schalken J Nees M Kallioniemi O: TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006, 66(21):10242-10246. 10.1158/ 0008-5472.CAN-06-1986 17079440
14. Yoshimoto M Joshua AM Chilton-Macneill S Bayani J Selvarajah S Evans AJ Zielenska M Squire JA: Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006, 8(6):465-469. 1601467 16820092 10.1593/neo.06283
15. Attard G Clark J Ambroisine L Fisher G Kovacs G Flohr P Berney D Foster CS Fletcher A Gerald WL Moller H Reuter V De Bono JS Scardino P Cuzick J Cooper CS: Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27(3):253-263. 10.1038/sj.onc.1210640 17637754
16. Mehra R Tomlins SA Shen R Nadeem O Wang L Wei JT Pienta KJ Ghosh D Rubin MA Chinnaiyan AM Shah RB: Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007, 20(5):538-544. 10.1038/modpathol.3800769 17334343
17. Barry M Perner S Demichelis F Rubin MA: TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology 2007, 70(4):630-633. 10.1016/j.urology.2007.08.032 17991527
18. Rajput AB Miller MA De Luca A Boyd N Leung S Hurtado-Coll A Fazli L Jones EC Palmer JB Gleave ME Cox ME Huntsman DG: Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007, 60(11):1238-1243. 10.1136/jcp.2006.043810 17259299
19. Demichelis F Fall K Perner S Andren O Schmidt F Setlur SR Hoshida Y Mosquera JM Pawitan Y Lee C Adami HO Mucci LA Kantoff PW Andersson SO Chinnaiyan AM Johansson JE Rubin MA: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 26(31):4596-4599. 10.1038/sj.onc.1210237 17237811
20. Saramaki OR Harjula AE Martikainen PM Vessella RL Tammela TL Visakorpi T: TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis. Clin Cancer Res 2008, 14(11):3395-3400. 10.1158/ 1078-0432.CCR-07-2051 18519769
21. Winnes M Lissbrant E Damber JE Stenman G: Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007, 17(5):1033-1036. 17390040
22. Liu W Ewing CM Chang BL Li T Sun J Turner AR Dimitrov L Zhu Y Sun J Kim JW Zheng SL Isaacs WB Xu J: Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 2007, 46(11):972-980. 10.1002/ gcc.20482 17654723
23. Lapointe J Kim YH Miller MA Li C Kaygusuz G van de Rijn M Huntsman DG Brooks JD Pollack JR: A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007, 20(4):467-473. 10.1038/modpathol.3800759 17334351
24. Penson DF Feng Z Kuniyuki A McClerran D Albertsen PC Deapen D Gilliland F Hoffman R Stephenson RA Potosky AL Stanford JL: General quality of life 2 years following treatment for prostate cancer: What influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 2003, 21(6):1147-1154. 10.1200/JCO.2003.07.139 12637483
25. Potosky AL Reeve BB Clegg LX Hoffman RM Stephenson RA Albertsen PC Gilliland FD Stanford JL: Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002, 94(6):430-437. 11904315
26. Stanford JL Wicklund KG McKnight B Daling JR Brawer MK: Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999, 8(10):881-886. 10548316
27. Makretsov N He M Hayes M Chia S Horsman DE Sorensen PH Huntsman DG: A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 2004, 40(2):152-157. 10.1002/gcc.20028 15101049
28. National Cancer Institute - Cancer Genetic Markers of Susceptibility: National Cancer Institute - Cancer Genetic Markers of Susceptibility http://cgems.cancer.gov/
29. Lubieniecka JM Cheteri MK Stanford JL Ostrander EA: Met160Val polymorphism in the TRMPSS2 gene and risk of prostate cancer in a population-based case-control study. Prostate 2004, 59(4):357-359. 10.1002/pros.20005 15065083
30. Biosystems A: Applied Biosystems. http://www.appliedbiosystems.com
31. Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc B 1972, 34:187-220.
32. Birger Y Catez F Furusawa T Lim JH Prymakowska-Bosak M West KL Postnikov YV Haines DC Bustin M: Increased tumorigenicity and sensitivity to ionizing radiation upon loss of chromosomal protein HMGN1. Cancer Res 2005, 65(15):6711-6718. 10.1158/0008-5472.CAN-05-0310 16061652
33. Bioinformatics UCSCG UCSC Genome Bioinformatics UCSC Genome Bioinformatics UCSC Genome Bioinformatics http://genome.ucsc.edu/
34. Cartegni L Wang J Zhu Z Zhang MQ Krainer AR: ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003, 31(13):3568-3571. 169022 12824367 10.1093/nar/gkg616
35. Helgeson BE Tomlins SA Shah N Laxman B Cao Q Prensner JR Cao X Singla N Montie JE Varambally S Mehra R Chinnaiyan AM: Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008, 68(1):73-80. 10.1158/0008-5472.CAN-07-5352 18172298
36. Tomlins SA Mehra R Rhodes DR Smith LR Roulston D Helgeson BE Cao X Wei JT Rubin MA Shah RB Chinnaiyan AM: TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006, 66(7):3396-3400. 10.1158/0008-5472.CAN-06-0168 16585160
37. Brown LA Huntsman D: Fluorescent in situ hybridization on tissue microarrays: Challenges and solutions. J Mol Histol 2007, 38(2):151-157. 10.1007/s10735-006-9069-y 17216303